{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:00:30Z","timestamp":1777622430331,"version":"3.51.4"},"reference-count":64,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Sports Med"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>The use of biologically based therapies is becoming a popular less-invasive therapy for relieving pain and promoting tissue regeneration. The most commonly used biologics are autologous adipose-derived products, bone marrow aspirations, and platelet-rich plasma (PRP). Birth tissue is a common allogenic source of biologics, including umbilical cord, placental membranes, and amniotic fluid. Injected biologics, depending on the indication and how they are processed, formulated, delivered, and promoted, can be subject to different regulatory pathways. The aim of this review is to provide an overview of these products and procedures and educate the musculoskeletal community about the relevant current Food and Drug Administration (FDA) regulations.<\/jats:p>","DOI":"10.1177\/0363546521990900","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T13:29:21Z","timestamp":1616765361000},"page":"3414-3421","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Food and Drug Administration\u2019s Position on Commonly Injected Biologic Materials in Orthopaedic Surgery"],"prefix":"10.1177","volume":"49","author":[{"given":"William H.","family":"Fang","sequence":"first","affiliation":[{"name":"Western University of Health Sciences, Pomona, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"C. Thomas","family":"Vangsness","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"bibr1-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2018.06.024"},{"key":"bibr2-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1390030"},{"key":"bibr3-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1177\/0363546510387517"},{"key":"bibr4-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1177\/0363546519881423"},{"key":"bibr5-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-720X.2009.00408.x"},{"key":"bibr6-0363546521990900","unstructured":"Eclipse PRP. Eclipse PRP\n                      \u00ae\n                      safety: intended use. Published 2018. Accessed May 14, 2020. https:\/\/eclipsemed.com\/eclipse-prp\/safety\/"},{"key":"bibr7-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.6058"},{"key":"bibr8-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1512592"},{"key":"bibr9-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1696672"},{"key":"bibr10-0363546521990900","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-D-17-00087"},{"key":"bibr11-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-219923"},{"key":"bibr12-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2018.02.906"},{"key":"bibr13-0363546521990900","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.17.01474"},{"key":"bibr14-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0123-4"},{"key":"bibr15-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1007\/s12178-018-9514-z"},{"key":"bibr16-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-007-0555-7"},{"key":"bibr17-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609583"},{"key":"bibr18-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1053\/j.otsm.2016.12.002"},{"key":"bibr19-0363546521990900","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.K.00430"},{"key":"bibr20-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2005-0235"},{"key":"bibr21-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1177\/0363546517697682"},{"key":"bibr22-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.04.002"},{"key":"bibr23-0363546521990900","unstructured":"Osiris Therapeutics Inc. Grafix Billing Guide 2018. Published 2018. Updated 2019. Accessed May 14, 2020. http:\/\/www.osiris.com\/grafix\/wp-content\/uploads\/2015\/01\/2018-Billing-Guide-for-HOPD-FINAL-GR18003REV00.pdf"},{"key":"bibr24-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1089\/biores.2016.0024"},{"key":"bibr25-0363546521990900","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.19.00266"},{"key":"bibr26-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4837930"},{"key":"bibr27-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2018.08.060"},{"key":"bibr28-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.9.1021"},{"key":"bibr29-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1353\/pbm.2018.0025"},{"key":"bibr30-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-018-06756-9"},{"key":"bibr31-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1177\/0363546519867933"},{"key":"bibr32-0363546521990900","unstructured":"United States v Regenerative Sciences LLC\n                      , 741 F.3d 1314 (D.C. Cir. 2014)."},{"key":"bibr33-0363546521990900","unstructured":"United States v Regenerative Sciences LLC\n                      , 878 F.Supp.2d 248 (D.C. Cir. 2012)."},{"key":"bibr34-0363546521990900","unstructured":"US Food and Drug Administration. 510(k) premarket notification. Progenikine Concentrating System 25 ML System. Published 2019. Updated March 30, 2020. Accessed March 26, 2020. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K191564"},{"key":"bibr35-0363546521990900","unstructured":"US Food and Drug Administration. 510(k) premarket notification, BK060007\u2014Autologel System. Published 2007. Updated March 23, 2020. Accessed March 25, 2020. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=BK060007"},{"key":"bibr36-0363546521990900","unstructured":"US Food and Drug Administration. 510(k) summary: ProKera Bio-Tissue, Inc. Published2003. Updated December 12, 2003. Accessed April 9, 2020. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf3\/k032104.pdf"},{"key":"bibr37-0363546521990900","unstructured":"US Food and Drug Administration. Approved cellular and gene therapy products. Published 2019. Updated March 29, 2019. Accessed March 27, 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products"},{"key":"bibr38-0363546521990900","unstructured":"US Food and Drug Administration. Center for Biologics Evaluation and Research (CBER). Published 2019. Updated September 13, 2019. Accessed March 27, 2020. https:\/\/www.fda.gov\/about-fda\/fda-organization\/center-biologics-evaluation-and-research-cber"},{"key":"bibr39-0363546521990900","unstructured":"US Food and Drug Administration. CFR\u2014Code of Federal Regulations Title 21. Published 2019. Updated April 1, 2019. Accessed April 1, 2020. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=1271"},{"key":"bibr40-0363546521990900","unstructured":"US Food and Drug Administration. Consumers (medical devices). Published 2019. Updated April 9, 2019. Accessed March 25, 2020. https:\/\/www.fda.gov\/medical-devices\/resources-you-medical-devices\/consumers-medical-devices#What_is_the_difference_between_Cleared_and_Approved"},{"key":"bibr41-0363546521990900","unstructured":"US Food and Drug Administration. Cord blood banking\u2014information for consumers. Published 2018. Updated March 23, 2018. Accessed March 26, 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/consumers-biologics\/cord-blood-banking-information-consumers"},{"key":"bibr42-0363546521990900","unstructured":"US Food and Drug Administration. De novo classification request. Published 2019. Updated November 20, 2019. Accessed April 1, 2020. https:\/\/www.fda.gov\/medical-devices\/premarket-submissions\/de-novo-classification-request"},{"key":"bibr43-0363546521990900","unstructured":"US Food and Drug Administration. Emergency use authorizations. Published 2020. Accessed May 14, 2020. https:\/\/www.fda.gov\/medical-devices\/emergency-situations-medical-devices\/emergency-use-authorizations"},{"key":"bibr44-0363546521990900","unstructured":"US Food and Drug Administration. FDA organization. Published 2020. Accessed March 22, 2020. https:\/\/www.fda.gov\/about-fda\/fda-organization"},{"key":"bibr45-0363546521990900","unstructured":"US Food and Drug Administration. FDA warns about stem cell therapies. Published 2019. Updated September 3, 2019. Accessed March 6, 2020. https:\/\/www.fda.gov\/consumers\/consumer-updates\/fda-warns-about-stem-cell-therapies"},{"key":"bibr46-0363546521990900","unstructured":"US Food and Drug Administration. How to study and market your device. Published 2019. Accessed March 24, 2020. https:\/\/www.fda.gov\/medical-devices\/device-advice-comprehensive-regulatory-assistance\/how-study-and-market-your-device"},{"key":"bibr47-0363546521990900","first-page":"29949","volume":"2005","author":"US Food and Drug Administration","year":"1271","journal-title":"Fed Regist"},{"key":"bibr48-0363546521990900","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"bibr49-0363546521990900","unstructured":"US Food and Drug Administration. Premarket approval (PMA). Published 2019. Accessed March 24, 2020. https:\/\/www.fda.gov\/medical-devices\/premarket-submissions\/premarket-approval-pma"},{"key":"bibr50-0363546521990900","unstructured":"US Food and Drug Administration. Ranfac Fat Aspiration Transfer Syringe (FATS) Procedure Pack. Published 2015. Accessed March 26, 2020. https:\/\/regenacelltherapy.com\/wp-content\/uploads\/ultimatemember\/temp\/K150156-fat-kit-procedure-pack-pdf"},{"key":"bibr51-0363546521990900","unstructured":"US Food and Drug Administration. Reference product exclusivity for biological products filed under Section 351(a) of the PHS Act. Published 2014. Accessed January 23, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/reference-product-exclusivity-biological-products-filed-under-section-351a-phs-act"},{"key":"bibr52-0363546521990900","unstructured":"US Food and Drug Administration. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. Published 2017. Accessed March 16, 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal"},{"key":"bibr53-0363546521990900","unstructured":"US Food Drug Administration. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. Published 2018. Updated December 2017. Accessed March 26, 2020. https:\/\/www.federalregister.gov\/documents\/2017\/11\/17\/2017-24838\/regulatory-considerations-for-human-cells-tissues-and-cellular-and-tissue-based-products-minimal."},{"key":"bibr54-0363546521990900","unstructured":"US Food and Drug Administration. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. Published 2020. Updated July 2020. Accessed July 30, 2020. https:\/\/www.fda.gov\/media\/109176\/download"},{"key":"bibr55-0363546521990900","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"bibr56-0363546521990900","unstructured":"US Food and Drug Administration. Shippert Medical Technologies 510k Application\u2014Tissu-Trans. Published 2005. Updated July 1, 2005. Accessed March 26, 2020. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf5\/K050797.pdf"},{"key":"bibr57-0363546521990900","unstructured":"US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, MD, on the FDA\u2019s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine. Published August 28, 2017. Accessed January 23, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-fdas-new-policy-steps-and-enforcement-efforts-ensure"},{"key":"bibr58-0363546521990900","unstructured":"US Food and Drug Administration. Statement on stem cell clinic permanent injunction and FDA\u2019s ongoing efforts to protect patients from risks of unapproved products. Published 2019. UpdatedJune 25, 2019. Accessed March 27, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-stem-cell-clinic-permanent-injunction-and-fdas-ongoing-efforts-protect-patients-risks"},{"key":"bibr59-0363546521990900","unstructured":"US Food and Drug Administration. Title 21: Food and Drugs; Part 640\u2014Additional Standards for Human Blood and Blood Products; Subpart D\u2014Plasma. Published 2020. Accessed April 1, 2020. https:\/\/www.ecfr.gov\/cgi-bin\/text-idx?SID=a9af1dccaf1136f06348fb8a753290ff&mc=true&node=se21.7.640_134&rgn=div8"},{"key":"bibr60-0363546521990900","unstructured":"US Food and Drug Administration. Understanding unapproved use of approved drugs \u201coff label.\u201d Published 2018. Updated February 5, 2018. Accessed March 26, 2020. https:\/\/www.fda.gov\/patients\/learn-about-expanded-access-and-other-treatment-options\/understanding-unapproved-use-approved-drugs-label"},{"key":"bibr61-0363546521990900","doi-asserted-by":"crossref","unstructured":"Van Batavia J, Goldenberg S. FDA Device Regulation: 510 (k), PMA. Academic Entrepreneurship for Medical and Health Scientists. 2019;1(3):4. Accessed January 23, 2021. https:\/\/repository.upenn.edu\/ace\/vol1\/iss3\/4\/","DOI":"10.21428\/b2e239dc.40f6dbdc"},{"key":"bibr62-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1016\/j.arthro.2015.03.014"},{"key":"bibr63-0363546521990900","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.04.017"},{"key":"bibr64-0363546521990900","unstructured":"Zimmer Biomet. Biologics U.S. Product Portfolio. Indications for Use\u2014 Please see package inserts for additional device information\/labeling. Published 2015. Accessed April 2, 2020. https:\/\/www.zimmerbiomet.com\/content\/dam\/zimmer-biomet\/medical-professionals\/foot-and-ankle\/amniorepair-allograft\/Biologics-Comprehensive-Brochure.pdf"}],"container-title":["The American Journal of Sports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0363546521990900","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0363546521990900","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0363546521990900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:49:15Z","timestamp":1777369755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0363546521990900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1177\/0363546521990900"],"URL":"https:\/\/doi.org\/10.1177\/0363546521990900","relation":{},"ISSN":["0363-5465","1552-3365"],"issn-type":[{"value":"0363-5465","type":"print"},{"value":"1552-3365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]}}}